All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On Wednesday 27 March 2019, Oral Session 20 (OS20) took place at the 45th Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT), Frankfurt, DE. During that session, Abstract OS20-2 was presented by Yongxian Hu from Zhejiang University, Hangzhou, CN.
In an attempt to improve the response rates and lower the toxicity with chimeric antigen receptor T-cell (CAR-T) therapy in B-cell non-Hodgkin lymphoma (B-NHL), the preliminary clinical evaluation of a dual targeting CD19 and CD22 CAR-T construct was presented here. The primary aim of this study was to assess the safety of the dual CAR-T construct. The investigators also compared the efficacy of the dual CAR-T construct to a single-targeting CD19 CAR-T construct. The cytotoxicity of the dual CAR-T construct was assessed in vitro and in mouse models in vivo prior to this in-human preliminary trial.
Characteristic |
CD19 single CAR-T group |
Dual CD19/CD22 CAR-T group |
---|---|---|
Median age (range) |
47.8 (27−65) years |
45.6 (25−65) years |
Male patients |
55.6% |
54.5% |
Disease type |
|
|
DLBCL |
88.9% |
81. 8% |
Burkitt lymphoma |
0% |
9.1% |
SLL/CLL |
11.1% |
0% |
Lymphoblastic lymphoma |
0% |
9.1% |
Prior lines of treatment |
|
|
2−3 |
22.2% |
27.2% |
4−5 |
33.3% |
36.3% |
> 5 |
44.4% |
36.3% |
Disease stage |
|
|
I−II |
22.2% |
18.2% |
III−IV |
77.8% |
81.8% |
Refractory status at study entry |
|
|
Primary refractory |
44.4% |
36.4% |
Refractory to ≥ 2 lines |
55.6% |
63.6% |
Relapse after auto-SCT |
22.2% |
18.2% |
Promising preliminary in-human results for the dual CD19/CD22 CAR-T construct with B-NHL patients achieving higher CR and ORR, with low severe CRS rates, compared to the standard CD19 single CAR-T construct. More in-human studies and of a larger scale with extended observation periods are needed to further validate these preliminary results.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox